IMM ImmuPharma plc

0.0317USD2.405 GBp · LSE-6.05%Mkt Cap: 19.80M USDP/E: —

ImmuPharma plc, together with its subsidiaries, engages in the research, development, and commercialization of peptide-based therapeutics for autoimmune diseases, infectious diseases, and metabolic disorders in the Unite…

Key Statistics

Company
Market Cap19.80M USD
Enterprise Value20.16M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-2.38M USD
Revenue/Share—
Last Price0.0317 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees7
CountryGB
SectorHealthcare
IndustryBiotechnology
ISINGB0033711010
Valuation
P/E (Trailing)—
P/E (Forward)-0.01
PEG—
EV/EBITDA-6.32
EV/Revenue—
P/S—
P/B8.02
EPS (TTM)-0.01 USD
EPS (Forward)-4.46 USD
52W Range
0.03160% of range0.1514
52W High0.1514 USD
52W Low0.0316 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-263.18%
ROA-96.20%
ROIC—
ROCE-368.95%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-3.12M USD
CapEx (TTM)2.18K USD
FCF Margin—
FCF Yield-22.47%
Net Debt-916.31K USD
Net Debt/EBITDA0.29
Net Debt/FCF—
Balance Sheet
Debt/Equity—
Current Ratio1.34
Quick Ratio0.78
Book Value/Sh0.0040 USD
Cash/Share0.0013 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div DateDec 14, 2021
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.625.29M
Float606.17M
Insiders4.96%
Institutions16.29%
Technical
SMA 500.0462 (-31.4%)
SMA 2000.0587 (-46.0%)
Beta3.00
S&P 52W Chg12.08%
Avg Vol (30d)3.17M
Avg Vol (10d)3.95M
Technical Indicators
RSI (14)34.5
MACD-0.2915
MACD Signal-0.2084
MACD Hist.-0.0831
BB Upper0.0544 USD
BB Middle0.0419 USD
BB Lower0.0295 USD
BB Width59.45%
ATR (14)0.0088 USD
Vol Ratio (20d)0.95x

About ImmuPharma (LON: IMM)

›

ImmuPharma (LON: IMM) is listed on the London Stock Exchange, where its shares trade in pence sterling (GBp). It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 7 employees.

The shares were at 2.405 GBp on 19 November 2026, down 77.1% over 52 weeks. Its 52-week range is 2.400 GBp to 11.50 GBp, and it trades at the bottom of that range.

Its market capitalisation is 15.04M GBP.

ImmuPharma reports return on equity of -263.2% and an operating margin of 0.0%.

It holds more cash than debt, a net cash position of 695.84K GBP. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health.